drugset / Trial / NCT00434330
Peginesatide for Maintenance Treatment of Anemia in Participants on Hemodialysis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to determine the dose ranges of peginesatide administered intravenously or subcutaneously that maintained hemoglobin in participants on dialysis whose hemoglobin values were stable on epoetin (alfa or beta).
Timeline
- Start
- 2006-12
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | peginesatide | Peptide | 0.04 mg/kg | Subcutaneous |
| Subject | peginesatide | Peptide | 0.05 mg/kg | Subcutaneous |
| Subject | peginesatide | Peptide | 0.075 mg/kg | Subcutaneous |
| Subject | peginesatide | Peptide | 0.1 mg/kg | Subcutaneous |